Kane Biotech (TSE:KNE) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kane Biotech Inc. has entered into a global licensing agreement with Omni Bioceutical Innovations for the distribution of its coactiv+™ scalp care product line. The five-year deal allows Omni to market Kane’s innovative scalp detoxifier under their brand, targeting the medical aesthetics market. The partnership is poised to leverage the product’s proven efficacy in addressing common scalp conditions without harsh chemicals.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
